Ken Griffin Scynexis Inc Put Options Transaction History

Citadel Advisors LLC

  • $509 Billion
  • Q1 2024

Put Options

5 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2023

Nov 14, 2023
BUY
$1.93 - $3.64 $10,036 - $18,928
5,200 Added 120.93%
9,500 $21,000
Q2 2023

Aug 14, 2023
SELL
$2.38 - $3.67 $64,260 - $99,090
-27,000 Reduced 86.26%
4,300 $12,000
Q1 2023

May 15, 2023
BUY
$1.15 - $3.0 $26,449 - $69,000
23,000 Added 277.11%
31,300 $93,000
Q4 2022

Feb 14, 2023
SELL
$1.46 - $2.49 $3,942 - $6,723
-2,700 Reduced 24.55%
8,300 $12,000
Q3 2022

Nov 14, 2022
SELL
$1.83 - $2.93 $10,431 - $16,701
-5,700 Reduced 34.13%
11,000 $26,000

Others Institutions Holding SCYX

# of Institutions
57
Shares Held
15.4M
Call Options Held
0
Put Options Held
12.9K
View Full List

About SCYNEXIS INC

SCYX Quotes by TradingView
  • Ticker SCYX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 32,651,800
  • Market Cap $63.7M
  • Description
  • SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...
More about SCYX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email